Holen Sie sich die Stockscreener-App
114.44
1.67%
-1.94
Handel nachbörslich:
114.43
-0.010
-0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$116.38
Offen:
$118.15
24-Stunden-Volumen:
3.22M
Relative Volume:
1.73
Marktkapitalisierung:
$17.49B
Einnahmen:
$4.29B
Nettoeinkommen (Verlust:
$703.00M
KGV:
25.64
EPS:
4.4635
Netto-Cashflow:
$993.00M
1W Leistung:
-14.35%
1M Leistung:
-21.37%
6M Leistung:
+17.52%
1J Leistung:
+10.50%
1-Tages-Spanne:
$112.65
$118.15
1-Wochen-Bereich:
$112.65
$128.16
52-Wochen-Spanne:
$68.70
$155.53
Illumina Inc Stock (ILMN) Company Profile
Firmenname
Illumina Inc
Sektor
Branche
Telefon
(858) 202-4500
Adresse
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
114.44 | 17.78B | 4.29B | 703.00M | 993.00M | 4.4635 |
|
TMO
Thermo Fisher Scientific Inc
|
509.82 | 198.06B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
214.94 | 155.50B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
617.20 | 51.80B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
124.88 | 36.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.83 | 32.29B | 3.11B | 648.81M | 602.27M | 10.88 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-07-11 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Bestätigt | Citigroup | Neutral |
| 2025-02-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-02-10 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-11-12 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-08-28 | Hochstufung | Argus | Hold → Buy |
| 2024-08-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-11-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Eingeleitet | Bernstein | Underperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Neutral |
| 2023-01-25 | Herabstufung | Argus | Buy → Hold |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Perform |
| 2022-12-12 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-04 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-07-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Hochstufung | Stifel | Hold → Buy |
| 2022-01-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Eingeleitet | Barclays | Underweight |
| 2020-12-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-10-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Herabstufung | Stifel | Buy → Hold |
| 2020-09-22 | Herabstufung | UBS | Buy → Neutral |
| 2020-09-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Illumina Inc Aktie (ILMN) Neueste Nachrichten
Illumina Q4 Earnings & Revenues Top Estimates, Stock Dips - Zacks Investment Research
Illumina's (NASDAQ:ILMN) Profits Appear To Have Quality Issues - Yahoo Finance
5 Insightful Analyst Questions From Illumina's Q4 Earnings Call - Finviz
Insider Buying: Scott Gottlieb Acquires Shares of Illumina Inc (ILMN) - GuruFocus
Scott Gottlieb Buys 200 Shares of Illumina (NASDAQ:ILMN) Stock - MarketBeat
Ngs Oncology Market Is Going to Boom | Illumina • Roche • Thermo Fisher Scientific - openPR.com
Simplifying library prep: All in a day’s work for Louise Fraser - Illumina
Illumina Looks To Clinical Consumables And China Restart To Offset Intensifying NGS Price Pressure - Citeline News & Insights
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - GlobeNewswire Inc.
Spatial Genomics and Transcriptomics Market size to cross - openPR.com
Illumina, Inc. $ILMN Shares Sold by GUARDCAP ASSET MANAGEMENT Ltd - MarketBeat
Multiomics Market Forecast Through 2033: Size, Share, Trends, - openPR.com
My path to Illumina - Illumina
Unlocking Illumina (ILMN) International Revenues: Trends, Surprises, and Prospects - Nasdaq
This Week in Chancery Court: Trump Media SPAC Appeal, Illumina - Bloomberg Law News
Illumina Crash 10% on Earnings: Why the Stock Could Rebound to $185 in 2026 - TIKR.com
Illumina, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - 富途牛牛
Is Illumina’s (ILMN) Clinical Consumables Surge Quietly Redefining Its Core Investment Story? - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Illumina (ILMN) and Ocular Therapeutix (OCUL) - The Globe and Mail
Illumina (ILMN) stock slides 10% after 2026 outlook puts China, research demand back in focus - TechStock²
Illumina, Inc.'s (NASDAQ:ILMN) Business Is Yet to Catch Up With Its Share Price - 富途牛牛
Illumina Enters Oversold Territory (ILMN) - Nasdaq
UBS Adjusts Illumina Price Target to $135 From $120, Maintains Neutral Rating - marketscreener.com
Molina Healthcare, Coty, Illumina, Amazon and other big stocks moving lower in Friday's pre-market session - MSN
Principal Financial Group Inc. Sells 17,431 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Q4 2025 Earnings Call Transcript - Insider Monkey
Illumina revenue up 5% to USD 1.16B in Q4 2025 - Medical Buyer
ILMN Q4 Deep Dive: Clinical Consumables Growth, Multiomics Expansion, and Margin Momentum - Yahoo Finance
Illumina Q4 2025 slides: Clinical growth accelerates as NovaSeq X transition advances By Investing.com - Investing.com South Africa
Illumina Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Illumina beats Q4 2025 EPS forecast by 10.66% - Investing.com Canada
Illumina (ILMN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Illumina Q4 2025 slides: Clinical growth accelerates as NovaSeq X transition advances - Investing.com
Illumina Inc (NASDAQ:ILMN) Stock Falls Despite Q4 Earnings Beat on Cautious 2026 Outlook - Chartmill
Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Illumina (NASDAQ:ILMN) Reports Bullish Q4 CY2025 - Finviz
Illumina (NASDAQ:ILMN) Posts Quarterly Earnings Results - MarketBeat
Illumina: Q4 Earnings Snapshot - kens5.com
Illumina shares tumble as flat revenue disappoints investors By Investing.com - Investing.com South Africa
Illumina (NASDAQ:ILMN) Issues FY 2026 Earnings Guidance - MarketBeat
Illumina Inc. Q4 Profit Advances - Nasdaq
Illumina Q4 Non-GAAP Earnings, Revenue Rise; 2026 Outlook Set - marketscreener.com
Illumina Q4 Earnings Summary & Key Takeaways - Benzinga
Earnings Flash (ILMN) Illumina, Inc. Reports Q4 Revenue $1.16B, vs. FactSet Est of $1.12B - marketscreener.com
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 - TradingView
Illumina earnings loom as investors seek clarity on 2026 outlook By Investing.com - au.investing.com
Illumina Wildlife Genomics Deal Highlights New Conservation And Valuation Story - Sahm
Insights Into Illumina (ILMN) Q4: Wall Street Projections for Key Metrics - Yahoo Finance
Multi-Omics Market Set for Explosive Growth to USD 33.25 Billion - openPR.com
San Diego Zoo’s Frozen Zoo Gets Genomic Boost - Newsradio 600 KOGO
Synthetic Biology Market Set for Explosive Growth to USD 67.47 - openPR.com
Finanzdaten der Illumina Inc-Aktie (ILMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):